



Top 20 Global Therapeutic Classes, 2010, Total Audited Markets

	2010 rank (US\$)	2010 Sales (US\$ MN)	% Growth 2010 (LC\$)	2009 Sales (US\$ MN)	% Growth 2009 (LC\$)	2008 Sales (US\$ MN)	% Growth 2008 (LC\$)	2007 Sales (US\$ MN)	% Growth 2007 (LC\$)	2006 Sales (US\$ MN)	% Growth 2006 (LC\$)
Global Market	0	\$ 791,449	5.2	\$ 752,022	6.7	\$ 727,067	5.0	\$ 671,164	6.3	\$ 609,614	6.8
Oncologics	1	\$ 55,972	6.7	\$ 52,372	8.8	\$ 49,438	13.4	\$ 41,949	15.8	\$ 34,905	21.6
Lipid Regulators	2	\$ 36,400	2.0	\$ 35,281	4.9	\$ 34,445	(1.2)	\$ 34,141	(5.8)	\$ 35,358	7.9
Respiratory Agents	3	\$ 35,926	7.0	\$ 33,596	11.0	\$ 31,186	5.9	\$ 28,775	11.9	\$ 24,796	11.4
Antidiabetics	4	\$ 34,429	12.2	\$ 30,406	13.4	\$ 27,548	10.1	\$ 24,401	10.8	\$ 21,310	12.7
Anti-ulcerants	5	\$ 27,972	(6.5)	\$ 29,610	0.6	\$ 30,032	0.0	\$ 29,174	2.6	\$ 27,619	3.0
Angiotensin II Antagonists	6	\$ 26,630	4.5	\$ 25,209	11.5	\$ 22,998	13.3	\$ 19,418	14.0	\$ 16,405	15.2
Antipsychotics	7	\$ 25,412	9.0	\$ 23,248	4.6	\$ 22,742	7.7	\$ 20,693	11.4	\$ 18,060	11.7
Autoimmune agents	8	\$ 20,710	14.7	\$ 17,961	18.0	\$ 15,612	19.3	\$ 12,815	17.4	\$ 10,629	21.6
Antidepressants	9	\$ 20,216	3.4	\$ 19,416	(1.3)	\$ 20,194	1.1	\$ 19,581	(6.2)	\$ 20,374	3.6
HIV Antivirals	10	\$ 15,432	13.2	\$ 13,758	14.9	\$ 12,280	12.7	\$ 10,699	12.8	\$ 9,175	10.9
Platelet Aggr. Inhibitors	11	\$ 15,244	1.8	\$ 14,604	9.0	\$ 13,647	10.4	\$ 11,952	8.7	\$ 10,624	8.1
Vitamins & minerals	12	\$ 12,971	6.1	\$ 11,951	9.5	\$ 11,374	8.7	\$ 10,109	6.9	\$ 9,026	4.2
Anti-epileptics	13	\$ 12,553	(3.3)	\$ 12,995	(19.8)	\$ 16,792	9.8	\$ 15,136	13.7	\$ 12,955	11.3
Narcotic analgesics	14	\$ 12,011	6.4	\$ 11,235	8.6	\$ 10,534	8.9	\$ 9,530	12.9	\$ 8,219	(1.1)
Cephalosporins & combs	15	\$ 11,466	6.1	\$ 10,586	6.9	\$ 10,188	3.4	\$ 9,489	2.8	\$ 8,849	(4.8)
Non-Narcotic Analgesics	16	\$ 10,986	0.0	\$ 10,917	7.5	\$ 10,896	4.2	\$ 10,179	8.0	\$ 8,862	3.2
Vaccines	17	\$ 10,972	2.8	\$ 10,690	(1.6)	\$ 11,172	(0.6)	\$ 10,911	43.6	\$ 7,311	19.7
Erythropoietins	18	\$ 10,596	(2.3)	\$ 10,829	(4.1)	\$ 11,486	(13.0)	\$ 12,866	(8.4)	\$ 13,791	12.0
Anti-Rheumatics, Non-Steroidal	19	\$ 10,152	3.6	\$ 9,668	3.0	\$ 9,897	3.6	\$ 9,318	(2.8)	\$ 9,187	(3.9)
Multiple Sclerosis	20	\$ 9,844	13.8	\$ 8,712	16.8	\$ 7,716	19.9	\$ 6,245	8.8	\$ 5,533	8.4

Source: IMS Health Midas, December 2010

US\$: Sales and Rank are in US\$ with quarterly exchange rates

LC\$: Growth is in constant \$ to normalize for exchange rate fluctuations

Growth rates in US\$ are not recommended due to extreme fluctuations in the value of the dollar

Sales cover direct and indirect pharmaceutical channel wholesalers and manufacturers. The figures above include prescription and certain over the counter data and represent manufacturer prices.

Therapy classes are defined as:

Oncologics L1, L2 & Revlimid

Lipid Regulators C10A & C10C&C11

Respiratory Agents R3

Antidiabetics A10C,A10H,A10J,A10K,A10L,A10M,A10N,A10S,A10X

Anti-ulcerants A2B

Angiotensin II Antagonists C9C & C9D & C9X

Antipsychotics N5A

Autoimmune agents M1C & Remicade & Cimzia (from L4A)

Antidepressants N6A

HIV Antivirals J5C

Platelet Aggr. Inhibitors B1C

Vitamins & Minerals A11 & A12 & A13

Anti-epileptics N3A

Narcotic analgesics N2A

Cephalosporins & Combs J1D

Non-Narcotic Analgesics N2B

Vaccines J7

Erythropoietins B3C

Anti-Rheumatics, Non-Steroidal M1A

Multiple Sclerosis L3B2&Copaxone&Tysabri